FuturedMe
Tokyo
About FuturedMe
FuturedMe is a platform focused on protein degradation, designed to create novel small molecules as potential drug candidates. FuturedMe was established utilizing CANDDY™, a proprietary drug design technology developed by the Tokyo University of Science. CANDDY™ compounds promote the degradation, rather than the inhibition, of targets associated with various diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $6.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2019)
- Website: futuredme.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/futuredme-66395 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.